Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti

Samuel Pierre,Iryna Bocharova, Catherine Nguyen,Fabienne Homeus, Gaetane Julmiste, Youry Macius,Vanessa Rouzier,Patrice Severe,Marie Marcelle Deschamps,Colette Guiteau Moise,Clovy Bellot, Johnny Wu,Vanessa R Rivera,Rochelle Sun,Jean W Pape, Bernard Liautaud,Serena P Koenig

OPEN FORUM INFECTIOUS DISEASES（2021）

引用 0|浏览7

暂无评分

摘要

We compared viral suppression rates between patients who continued tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) vs switched to zidovudine (ZDV)/3TC in combination with a boosted protease inhibitor after failure of first-line efavirenz/TDF/3TC. We found higher rates of viral suppression with continued TDF/3TC compared with switching to ZDV/3TC.

查看译文

关键词

genotypic resistance, HIV, second-line therapy, tenofovir disoproxil fumarate, zidovudine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要